Desensitization outcomes
| Characteristic | n=186 |
| Median time in chemo unit, minutes (range) | 380 (325–630) |
| Median number of desensitization cycles, n (range) | 3 (1–28) |
| Successful completion of ≥3 cycles, n (%) | 104 (56%) |
| Breakthrough HSR during desensitization, n (%) | 79 (42%) |
| Reason for drug discontinuation, n (%) | |
| Progression of disease | 84 (45%) |
| Hypersensitivity reaction* | 41 (22%) |
| End of treatment | 38 (20%) |
| Other | 13 (7%) |
| Ongoing | 10 (5%) |
| Drugs discontinued due to breakthrough HSR (n=41)* | |
| Oxaliplatin | 20 (49%) |
| Carboplatin | 14 (34%) |
| Cisplatin | 2 (5%) |
| Paclitaxel | 2 (5%) |
| Trastuzumab | 2 (5%) |
| Liposomal doxorubicin | 1 (2%) |
HSR, hypersensitivity reaction.